NeurologyLive® Friday 5 — April 14, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: FDA Places Partial Hold on Evobrutinib Initiation in Newly Enrolled Patients With MS

Because of safety concerns, the FDA has placed a partial clinical hold on the initiation of evobrutinib (EMD Serono), an investigational Bruton’s tyrosine kinase (BTK) inhibitor, in new patients and those with less than 70 days of exposure.

2: Peer Exchange: Safety Considerations for Therapies in NMOSD

In episode 6 of this Peer Exchange series on "Updates in the Management of Neuromyelitis Optica Spectrum Disorder Care (NMOSD)", experts in neurology discuss the safety concerns of a plethora of new treatments for NMOSD.

3: NeuroVoices: Julie Pilitsis, MD, PhD, MBA, on Weighing Surgical Options for Degenerative Conditions

In the latest edition of our in-depth Q&A series, the dean of the Charles E. Schmidt College of Medicine at Florida Atlantic University provided perspective on invasive procedures for degenerative conditions and when deep brain stimulation is needed.

4: Assessing New Long-Term Efficacy and Durability Data of Zolgensma for Spinal Muscular Atrophy

Sitra Tauscher-Wisniewski, MD, vice president clinical development and analytics, Novartis Gene Therapies, talked about new data on the gene therapy presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas.

5: Evolving Role of Deep Brain Stimulation for Parkinson Disease, Essential Tremor: Julie Pilitsis, MD, PhD, MBA

The dean of the Charles E. Schmidt College of Medicine at Florida Atlantic University provided perspective on the advances of DBS and other invasive procedures for patients with degenerative disorders. [WATCH TIME: 4 minutes]